Swiss cancer giant Roche (ROG: SIX) has submitted for approval in the USA to market Tecentriq (atezolizumab) plus Avastin (bevacizumab) for certain people with hepatocellular carcinoma (HCC).
The submission, which is based on the results of the Phase III IMbrave150 study, relates to people with unresectable HCC who have not received prior systemic therapy.
Full results, presented at the European Society for Medical Oncology (ESMO) Asia Congress in November 2019, showed a reduced risk of death by 42%, compared with Nexavar (sorafenib), from Bayer (BAYN: DE).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze